The Business Times
SUBSCRIBERS

Israeli biotech firm surges on mystery firm's nameless analyst note

Published Wed, Feb 4, 2015 · 09:50 PM
Share this article.

Tel Aviv

WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.

The two-page report from Acceleron Equity Research dated Jan 26 was published on Acceleron's website and distributed by Marketwired, a press-release distribution service, the next day. The site and research document don't identify anyone involved with the firm, while the press release about the report lists a media contact named M Morhamus. The report says the analysts who wrote it don't own Pluristem stock, but that employees and officers of Acceleron might.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Technology

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here